Medical Grand Rounds

*Presented by*

Yale School of Medicine, Department of Internal Medicine,

Section of Endocrinology & Metabolism

Ania Jastreboff, MD, PhD

Associate Professor; Director, Weight Management & Obesity Prevention; Medical Director, Yale Stress Center

“Anti-Obesity Pharmacotherapy:

*The Future Is Now*!”

**Date: September 23, 2021 Time: 8:30-9:30am**

**Location:** [**https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09**](https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09)

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION:**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE:**

**Attending physicians, house staff, fellows, medical students, PA’s**

**NEEDS ASSESSMENT:**

Obesity is a common, serious, and costly disease. Clinicians need to know about the use of anti-obesity medications for treatment of patients with obesity, including new therapeutic agents under development.

**LEARNING OBJECTIVES:**

1. Identify barriers to implementing obesity pharmacotherapy

2. Describe available anti-obesity medication used in the treatment of patients with obesity and gain knowledge about new agents in development

3. Explain key concepts in treating patients with obesity with anti-obesity medications

**DESIGNATION STATEMENT**

*The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.*

**FACULTY DISCLOSURES:**

Course Director: Vincent Quagliarello, MD - None

Speaker: Ania Jastreboff, MD- Novo Nordisk; Consulting fee; Scientific advisory board

Eli Lilly; Consulting fee; Scientific advisory board

Boehringer Ingelheim; Consulting fee; Consulting

Intellihealth; Consulting fee; Scientific advisory board

Scholar Rock; Consulting fee; Consulting

Pfizer; Consulting fee; Scientific advisory board

American Diabetes Association; Research support; Grant PI

Eli Lilly; Research support; Multi-center study site PI

Novo Nordisk; Research support; Multi-center study site PI

NIH/NIDDK; Research support; Grant PI

Pangolin Therapeutics (spouse); Spouse - Stock options; Spouse - advisory committee

Elucidata (spouse) Spouse - Stock options; Spouse - co-founder

Agios (spouse); Spouse - Consulting fee; Spouse - consulting

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.